4.7 Article

The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device

Journal

ACS CENTRAL SCIENCE
Volume 6, Issue 11, Pages 2046-2052

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acscentsci.0c00855

Keywords

-

Funding

  1. ERC [638661]
  2. Royal Society (Industry Fellowship) [191037]
  3. BBSRC MIBTP program [BB/M01116X/1]
  4. Iceni Diagnostics Ltd
  5. EPSRC [EP/R511808/1]
  6. BBSRC [BB/S506783/1, BB/P01948X/1, BB/R002517/1, BB/S003339/1]
  7. MRC DTP [MR/N014294/1]
  8. Wellcome Trust [200870/Z/16/Z]
  9. Leverhulme Trust [RPG-2019087]
  10. Wellcome [208361/Z/17/Z]
  11. MRC [MR/S009213/1]
  12. Wellcome Trust [200870/Z/16/Z] Funding Source: Wellcome Trust
  13. BBSRC [BB/S003339/1, 1898615, BB/P01948X/2, BB/P01948X/1, BB/R002517/1] Funding Source: UKRI
  14. MRC [MR/S009213/1] Funding Source: UKRI

Ask authors/readers for more resources

There is an urgent need to understand the behavior of of the novel coronavirus (SARS-COV-2), which is the causative agent of COVID-19, and to develop point-of-care diagnostics. Here, a glyconanoparticle platform is used to discover that N-acetyl neuraminic acid has affinity toward the SARS-COV-2 spike glycoprotein, demonstrating its glycan-binding function. Optimization of the particle size and coating enabled detection of the spike glycoprotein in lateral flow and showed selectivity over the SARS-COV-1 spike protein. Using a virus-like particle and a pseudotyped lentivirus model, paper-based lateral flow detection was demonstrated in under 30 min, showing the potential of this system as a low-cost detection platform.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available